Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The First Affiliated Hospital of Henan University of Traditional Chinese Medicine | OTHER |
| China-Japan Friendship Hospital | OTHER |
| The First Affiliated Hospital of Zhengzhou University | OTHER |
Not provided
Not provided
Not provided
Not provided
This study, based on previous registration records, aims to explore the syndrome patterns, disease characteristics, and their interrelationships of IPF at different stages, grades, and in its natural course, thus providing a multidimensional interpretation of the syndrome patterns and characteristics of IPF.
This study, based on previous registration records, uses a cross-sectional survey design to collect demographic information, disease-related data, syndrome data, and auxiliary examination data from 2864 IPF patients in China. It aims to elucidate the syndrome types, disease characteristics, and the interrelationships between them of IPF at different stages, grades, and in its natural course.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants fill out the questionnaire | Participants fill out the questionnaire |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Disease Stage | Recording the disease staging of IPF patients. According to the Adult Idiopathic Pulmonary Fibrosis (Revised Edition) and Progressive Pulmonary Fibrosis: ATS/ERS/JRS/ALAT Official Clinical Practice Guidelines (2022 Edition), and the Chinese Expert Consensus on the Diagnosis and Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis, the disease staging evaluation of IPF is stable phase or acute exacerbation. | Evaluate at baseline. |
| Gender, age and physiologic variables (GAP)stage | Recording the GAP stage of IPF patients. GAP stage is a risk stratification method that quantifies the three core parameters of patients: gender, age, and physiological parameters, by calculating the total score and conducting risk stratification. | Evaluate at baseline. |
| Pulmonary function classification | Recording the pulmonary function classification of IPF patients. According to The Expert Consensus on the Diagnostic Criteria for Adult Lung Function in China, pulmonary function classification is divided into mild, moderate, and severe grades. | Evaluate at baseline. |
| Natural course | Recording the natural course of IPF patient. According to international research, the natural course of IPF can be divided into stable, slow progression, rapid progression, and recurrent acute exacerbation. The specific criteria are as follows: 1.stable: FVC annual decline<0.13L; 2. stable slow progression: FVC annual decline 0.13L-0.21L; 3. Rapid progress: FVC annual decline>0.21L; 4. Recurrent acute exacerbations: Annual number of acute exacerbations ≥ 1. | Evaluate at baseline. |
| The Traditional Chinese Medicine(TCM) Syndromes | Evaluate traditional Chinese medicine syndromes by collecting patients' symptoms, signs, and tongue pulse information. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Idiopathic pulmonary fibrosis (IPF) is a special type of idiopathic interstitial pneumonia, which is mainly manifested by irritating dry cough and progressive dyspnea.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| xueqing yu, Ph.D | Contact | +8613525518843 | yxqshi@163.com | |
| jiansheng li, Professor | Contact |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Henan University of Chinese Medicine | Zhengzhou | Henan | 450000 | China |
Not provided
| ID | Term |
|---|---|
| D054990 | Idiopathic Pulmonary Fibrosis |
| ID | Term |
|---|---|
| D011658 | Pulmonary Fibrosis |
| D017563 | Lung Diseases, Interstitial |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| Shanghai Pulmonary Hospital, Shanghai, China | OTHER |
Not provided
Not provided
Not provided
blood,Tongue coating
| Evaluate at baseline. |
| 6 Six Minute Walk Distance(6MWD) | 6MWD will be applied to evaluate the exercise capacity. The higher values indicate the better exercise capacity. | Evaluate at baseline. |
| The 30 - second sit - to - stand test(30s STS) | The 30 second sitting and standing test will be used to evaluate lower limb strength and cardiopulmonary function. | Evaluate at baseline. |
| A Tool to Assess Quality of life (ATAQ-IPF) total scores | ATAQ-IPF is currently a specialized scale for evaluating the quality of life, consisting of 13 dimensions and 74 items, with each item scored on a 1-5 scale. The higher the score, the worse the quality of life. | Evaluate at baseline. |
| St. George's respiratory questionnaire (SGRQ) total scores | SGRQ is a scale used to evaluate the quality of life of patients, which includes three dimensions: symptoms, mobility, and the impact of disease on daily life, with a total of 50 items. The total score range of SGRQ is usually between 0 and 100, with higher scores leading to poorer quality of life. | Evaluate at baseline. |
| Dyspnea | Dyspnea will be assessed by modified Medical Research Council(mMRC) scores. A score of 0-4 will be givenaccording to the degree of immediate dyspnea. A higher score indicates a worse condition. | Evaluate at baseline. |
| C-reactive protein (CRP) | The CRP level will be detected by ELISA technology. | Evaluate at baseline. |
| Krebs Von den Lungen-6（KL-6） | The KL-6 level will be detected by ELISA technology. | Evaluate at baseline. |
| The pulmonary artery systolic pressure(PASP) | The PASP will be measured byechocardiogram. | Evaluate at baseline. |
| The diameter of the pulmonary artery | The diameter of the pulmonary artery will be measured byechocardiogram. | Evaluate at baseline. |
| Forced vital capacity (FVC) | FVC will be applied to assess pulmonary function. | Evaluate at baseline. |
| FVC as the percentage of the predicted value (FVC%) | FVC% will be applied to assess pulmonary function. | Evaluate at baseline. |
| Diffusing capacity of the lungs for carbon monoxide (DLCO) | DLCO will be applied to assess pulmonary function. | Evaluate at baseline. |
| DLCO as the percentage of the predicted value (DLCO%) | DLCO% will be applied to assess pulmonary function. | Evaluate at baseline. |